Therapy of relapsed/refractory metastatic triple-negative breast cancer (mTNBC) with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): Phase II results.-Reference-Cited by-同舟云学术

Therapy of relapsed/refractory metastatic triple-negative breast cancer (mTNBC) with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): Phase II results.

Published:2016-06-20 Issue:18_suppl Volume:34 Page:LBA509-LBA509
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Bardia Aditya¹,Diamond Jennifer Robinson²,Messersmith Wells A.³,Mayer Ingrid A.⁴,Isakoff Steven J.¹,Abramson Vandana Gupta⁵,Berlin Jordan⁶,Starodub Alexander⁷,O'Shaughnessy Joyce⁸,Kalinsky Kevin⁹,Moroose Rebecca L.¹⁰,Shah Nikita C.¹⁰,Juric Dejan¹,Shapiro Geoffrey¹¹,Guarino Michael J.¹²,Ocean Allyson J.¹³,Wilhelm Francois¹⁴,Sharkey Robert M.¹⁵,Goldenberg David M.¹⁴,Vahdat Linda T.¹³

Affiliation:

1. Massachusetts General Hospital Cancer Center, Boston, MA;

2. University of Colorado Denver, Aurora, CO;

3. University of Colorado Cancer Center, Aurora, CO;

4. Vanderbilt-Ingram Comprehensive Cancer Center, Nashville, TN;

5. Vanderbilt University Medical Center, Nashville, TN;

6. Vanderbilt-Ingram Cancer Center, Nashville, TN;

7. Indiana University Health Goshen Center for Cancer Care, Goshen, IN;

8. Baylor University Medical Center, Texas Oncology, Dallas, TX;

9. Columbia University Medical Center, New York, NY;

10. UF Health Cancer Center at Orlando Health, Orlando, FL;

11. Dana-Farber Cancer Institute, Boston, MA;

12. Helen F. Graham Cancer Center at Christiana Care Health System, Newark, DE;

13. Weill Cornell Medical College, New York, NY;

14. Immunomedics, Inc., Morris Plains, NJ;

15. Immunomedics Inc., Morris Plains, NJ;

Abstract

LBA509 Notice of Retraction: “Therapy of relapsed/refractory metastatic triple-negative breast cancer (mTNBC) with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): Phase II results.” ASCO's Confidentiality Policy requires that abstracts be considered confidential and embargoed from the time of submission until the findings have been publicly released in conjunction with the ASCO Annual Meeting. Abstract LBA509, published in the 2016 ASCO Annual Meeting Proceedings Part II, violated this policy and was retracted from publication and presentation at the 2016 ASCO Annual Meeting.

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

http://ascopubs.org/doi/pdfdirect/10.1200/JCO.2016.34.18_suppl.LBA509

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Comprehensive Immunologic Portrait of Triple-Negative Breast Cancer;Translational Oncology;2018-04

2. Novel therapeutic strategies in the treatment of triple-negative breast cancer;Therapeutic Advances in Medical Oncology;2017-06-13